The neurotensin receptor antagonist SR 48692 decreases extracellular striatal GABA in rats.
Intracranial microdialysis was utilized to assess the effects of the novel neurotensin antagonist SR 48692 on extracellular gamma-amino-butyric acid (GABA) and glycine in the striatum. Subcutaneous injection of SR 48692 (0.2 mg/kg) significantly decreased extracellular striatal GABA levels, with peak decreases occurring 2-3 h post-injection. Injection of SR 48692 had no significant effect on glycine levels. These data suggest that endogenous neurotensin may modulate striatal GABA levels.
Chapman
M A
MA
Department of Psychology, Washington State University, Pullman 99164-4820, USA. chapmanp@wpogate.slu.edu
See
R E
RE
D000704:Analysis of Variance; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D005998:Glycine / Q000378:metabolism; D007279:Injections, Subcutaneous; D017551:Microdialysis; D011720:Pyrazoles / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018028:Receptors, Neurotensin / Q000037:antagonists & inhibitors*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D011720:Pyrazoles; D011804:Quinolines; D018028:Receptors, Neurotensin; C079087:SR 48692; D005680:gamma-Aminobutyric Acid; D005998:Glycine